Zobrazeno 1 - 10
of 25
pro vyhledávání: '"Caroline McKay"'
Autor:
Lisa Bloudek, Phoebe Wright, Caroline McKay, Christina Louise Derleth, Jennifer Susan Lill, Enrique Lenero, Zsolt Hepp, Scott David Ramsey, Sean D. Sullivan, Beth Devine
Publikováno v:
Current Oncology, Vol 30, Iss 4, Pp 3637-3647 (2023)
To compare efficacy outcomes for all approved and investigational first-line (1L) treatment regimens for locally advanced or metastatic urothelial carcinoma (la/mUC) with standard of care (SOC), a network meta-analysis (NMA) was conducted. A systemat
Externí odkaz:
https://doaj.org/article/78b13a372e34463d839cddbe2ba03964
Autor:
Amy P Abernethy, Ashwini Arunachalam, Thomas Burke, Caroline McKay, Xiting Cao, Rachael Sorg, David P Carbone
Publikováno v:
PLoS ONE, Vol 12, Iss 6, p e0178420 (2017)
To establish a baseline for care and overall survival (OS) based upon contemporary first-line treatments prescribed in the era before the introduction of immune checkpoint inhibitors, for people with metastatic non-small cell lung cancer (NSCLC) with
Externí odkaz:
https://doaj.org/article/40f05bf53e634a3cbdb1167ee3670a0a
Autor:
Brian Bloudek, Heidi S Wirtz, Zsolt Hepp, Jack Timmons, Lisa Bloudek, Caroline McKay, Matthew D Galsky
Publikováno v:
Clinical epidemiology. 14
Brian Bloudek,1 Heidi S Wirtz,2 Zsolt Hepp,2 Jack Timmons,1 Lisa Bloudek,1 Caroline McKay,3 Matthew D Galsky4 1Curta Inc., Seattle, WA, USA; 2Seagen Inc., Bothell, WA, USA; 3Astellas Pharma Global Development, Inc., Northbrook, IL, USA; 4Tisch Cancer
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::eb7f7ae9ff8e98933ffaf5ce94832893
https://pubmed.ncbi.nlm.nih.gov/36404878
https://pubmed.ncbi.nlm.nih.gov/36404878
Autor:
Marie-Hélène Lafeuille, Fuad Paramasivam, Melody Chang, Hela Romdhani, Lucio Gordan, Eric M Maiese, Caroline McKay
Publikováno v:
Drugs-Real World Outcomes
Background Some institutions have implemented a daratumumab intravenous rapid-infusion protocol in which patients with multiple myeloma (MM) receive their third and subsequent infusions within ~ 90 min instead of ≥ 3 h. Objective This study sought
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::4e3e041ad17171617ab2bcbc17931b28
https://doi.org/10.1007/s40801-020-00226-3
https://doi.org/10.1007/s40801-020-00226-3
Autor:
Cynthia J. Girman, Panagiotis Mavros, Jessica M. Franklin, Sebastian Schneeweiss, Rishi J. Desai, Macarius Donneyong, Mehul D. Patel, Caroline McKay, Leona E. Markson
Publikováno v:
Journal of Comparative Effectiveness Research. 6:613-625
Aim: To assess heterogeneity in adherence to medications in two example comparative effectiveness research studies. Patients & methods: We analyzed data from commercially insured patients initiating a statin or anticoagulant during 2005–2012. We ca
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::574e67001ffcd1c3362bebde768e903c
https://doi.org/10.2217/cer-2016-0095
https://doi.org/10.2217/cer-2016-0095
Autor:
Jens Bedke, Guru Sonpavde, Chunzhang Wu, Thomas Powles, Howard Gurney, Srikala S. Sridhar, Begoña P. Valderrama, Daniel Castellano, Ignacio Duran, Ronac Mamtani, Michiel S. van der Heijden, Jae-Lyun Lee, Jonathan E. Rosenberg, Helle Pappot, Christof Vulsteke, Yohann Loriot, Zsolt Hepp, Nobuaki Matsubara, Daniel P. Petrylak, Caroline McKay
Publikováno v:
Journal of Clinical Oncology. 39:4539-4539
4539 Background: In EV-301, a randomized, open-label phase 3 study (NCT03474107), enfortumab vedotin (EV), a Nectin-4–directed therapy, significantly prolonged median overall survival by ̃3.9 months and reduced the risk of death by 30% compared wi
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::8c4e21a5d86edf6d06aca2a99d3f5667
https://doi.org/10.1200/jco.2021.39.15_suppl.4539
https://doi.org/10.1200/jco.2021.39.15_suppl.4539
Autor:
Zach Weber, Noll L. Campbell, Newell E. McElwee, Caroline McKay, Wanzhu Tu, Jia Zhan, Roberta Ambeuhl
Publikováno v:
Pharmacotherapy: The Journal of Human Pharmacology and Drug Therapy. 36:196-202
To compare the frequencies of barriers to medication adherence reported by ambulatory older adults with a diagnosis of mild cognitive impairment (MCI) and ambulatory older adults with normal cognition.Cross-sectional study.Outpatient clinics within a
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::acd90b4d4c4e9b74dc4943a43106d6ec
https://doi.org/10.1002/phar.1702
https://doi.org/10.1002/phar.1702
Autor:
Niteesh K. Choudhry, Karandeep Singh, Joe Kimura, Alexis A. Krumme, Caroline McKay, Jessica M. Franklin, Newell E. McElwee
Publikováno v:
Pharmacoepidemiology and drug safetyREFERENCES. 28(10)
PURPOSE We sought to determine whether an association study using information contained in clinical notes could identify known and potentially novel risk factors for nonadherence to antihypertensive medications. METHODS We conducted a retrospective c
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::3998165ff90bbac950eb1faba6a657ba
https://pubmed.ncbi.nlm.nih.gov/31313427
https://pubmed.ncbi.nlm.nih.gov/31313427
Autor:
Alexis A. Krumme, Mufaddal Mahesri, Gregory Brill, Heather Black, Niteesh K. Choudhry, Jessica M. Franklin, Michael A. Fischer, Caroline McKay, Julie Barberio
BACKGROUND: Data on primary nonadherence remains sparse, due to a lack of data resources that combine information on medication prescribing and dispensing. In addition, previous work on primary nonadherence has used follow-up periods ranging from 30
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::cc5442d9fc796275c1436840e4592ab3
https://europepmc.org/articles/PMC6206334/
https://europepmc.org/articles/PMC6206334/
Autor:
Rachael Sorg, Xiting Cao, Caroline McKay, Thomas Burke, Ashwini Arunachalam, David P. Carbone, Amy P. Abernethy
Publikováno v:
PLoS ONE
PLoS ONE, Vol 12, Iss 6, p e0178420 (2017)
PLoS ONE, Vol 12, Iss 6, p e0178420 (2017)
Purpose To establish a baseline for care and overall survival (OS) based upon contemporary first-line treatments prescribed in the era before the introduction of immune checkpoint inhibitors, for people with metastatic non-small cell lung cancer (NSC
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::46490f73b0f345fab4c58694cd3d1096
http://europepmc.org/articles/PMC5482433
http://europepmc.org/articles/PMC5482433